IRIS

Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 210
Titolo Data di pubblicazione Autore(i) File
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis 1-gen-2005 Tolusso, B; Fabris, M; Caporali, R; Cuomo, Giovanna; Isola, M; Soldano, F; Montecucco, C; Valentini, Gabriele; Ferraccioli, G.
VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) AND DAS28 AS MEASURE OF RESPONSE TO TREATMENT IN PATIENTS UNDERGOING DIFFERENT THERAPEUTIC REGIMENS 1-gen-2005 Cuomo, Giovanna; Montagna, G. La; Molinaro, G.; Valentini, Gabriele
Echocardiographic alterations in systemic sclerosis: a longitudinal study. 1-gen-2005 Maione, S.; Cuomo, Giovanna; Giunta, A.; TANTURRI DE HORATIO, L.; LA MONTAGNA, G.; Manguso, F.; Alagia, I. A. M.; Valentini, Gabriele
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 1-gen-2006 Cuomo, Giovanna; Molinaro, G; La Montagna, G; Migliaresi, S; Valentini, Gabriele
[HAQ-DI Italian version in systemic sclerosis]. 1-gen-2006 La Montagna, G; Cuomo, Giovanna; Chiarolanza, I; Ruocco, L; Valentini, Gabriele
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 1-gen-2007 Paone, C.; Chiarolanza, I.; Cuomo, Giovanna; Ruocco, L.; Vettori, Serena; Menegozzo, M.; LA MONTAGNA, G.; Valentini, Gabriele
CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS 1-gen-2007 Vettori, Serena; Abbadessa, Salvatore; Chiarolanza, I.; Ruocco, L.; Cuomo, Giovanna; Maresca, L.; Leonardo, G.; Valentini, G.
HYPOCOMPLEMENTEMIA IN SYSTEMIC SCLEROSIS (SSC) 1-gen-2008 Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Valentini, G.
18. Imapired excerise performance in systemic sclerosis. Clinical correlations 1-gen-2008 Valentini, G.; Santoriello, C.; Cuomo, Giovanna; Polverino, F.; Ruocco, L.; Polverino, M. .
[Hypocomplementemia in systemic sclerosis]. 1-gen-2008 Cuomo, Giovanna; Abignano, G; Ruocco, L; Vettori, Serena; Valentini, Gabriele
MYCOPHENOLATE MOFETIL IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS 1-gen-2009 Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G. .
Effectiveness and safety of mycophenolate mofetil in the treatment of interstitial lung disease in patients with systemic sclerosis 1-gen-2009 Cuomo, Giovanna; G., Abignano; M., Iudici; A., Petrillo; G., Valentini
[FRI0311] CORRELATIONS BETWEEN CLINICAL FEATURES OF154 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND SHORT FORM36 (SF36) SCORES G. Cuomo, M. Iudici, G. Abignano, A. Petrillo, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Background: The quality of life is reduced in patients with systemic sclerosis (SSc) as evaluated by both disease specific (HAQ-DI; SHAQ) or generic questionnaires. The correlations between SF-36 scores and some disease features have not yet been explored. Objectives: To evaluate the relationships between health values as evaluated by SF-36 and clinical features in SSc patients. Methods: From 9/01/07 to 8/31/08 154 consecutive SSc patients (144 females; 10 males); aged from 20–82 years (median age 54), with disease duration from 1-47 years (median 10,5 years); attending the outpatient clinic of the Rheumatology Unit of Second University of Naples, were enrolled in the study. The scores of the eight areas of SF-36 General Health: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social function (SF), Role Emotional (RE) and Mental Health (MH), were evaluated in the range of 0–100, the higher values reflecting a better Quality of life (Qol). In addition two global series i.e. the Physical Component Summary Score (PCS) and the Mental Component Summary Score (MCS) were calculated. The patients were also investigated for disease subset (limited or diffuse); skin involvement by the modified Rodnan skin score; disability by HAQ-DI; disease activity by European Activity Index, and disease severity by Medsger severity scale. Results: SF36 score did not differ between the 31 patients with diffuse vs the 123 with limited disease All the items of SF36 were significantly correlated to activity Index (Rho from –0.28 to -0.32: p<0.0001) and HAQ-DI (Rho from -0.38 to -0.82: p<0.0001). GH resulted to correlate with mRss (Rho -0.17; p<0.05) The significant correlations between each item of the Medsger's severity scale and each item of SF36 are reported in table. PF RP BP GH VT SF RE MH PCS/MCS Sev_Gen (Rho) – – – – – – – – –/– Sev_Vasc(Rho) – – – – – – – – –/– Sev_Skin (Rho) – – – – – – – – –/– Sev_Joint (Rho) – – – -0.18* – – – – -0.21**/– Sev_muscle (Rho) -0.25** – – -0.16* -0.18* -0.22* – -0.20* -0.20*/– Sev_GI (Rho) -0.20* – – -0.22** – – – – –/– Sev_lung (Rho) -0.28*** – – -0.23** -0.17* -0.23** -0.22** – -0.19*/– Sev_Heart (Rho) – – -0.22* – – – – – -0.21*/– Sev_kidney (Rho) – – – – – – – – – *p<0.05; **p<0.001; ***p<0.0001. Conclusion: The present study, confirms that the Health Value, as evaluated by SF36, is diminished in SSc. Our study point out a previously univestigated correlation between SF-36 scores and disease activity. Disclosure of Interest: NONE declared Ann Rheum Dis 2009;68(Suppl3):459 Session: Scleroderma, myositis and related syndromes 1-gen-2009 Cuomo, Giovanna; Iudici, M.; Abignano, G.; Petrillo, A.; Valentini, G.
TWENTYFOUR-MONTH AZATHIOPRINE AS MAINTENANCE THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE TREATED WITH LOW DOSE CYCLOPHOSPHAMIDE PULSE THERAPY 1-gen-2009 Abignano, G.; Cuomo, Giovanna; Iudici, M.; Petrillo, A.; Valentini, G.
ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC). ULTRASONOGRAPHIC FEATURES OF HAND JOINTS 1-gen-2009 Cuomo, Giovanna; Zappia, M.; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G.
Sclerosi sistemica 1-gen-2009 Cuomo, Giovanna; Tirri, Rosella; Valentini, Gabriele
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes 1-gen-2009 Abignano, G.; Iudici, M.; Petrillo, A.; Cuomo, Giovanna; Valentini, Gabriele
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systematic literature research 1-gen-2009 Avouac, J.; Kowal-Bielecka, O.; Landewe, R.; Chwiesko, S.; Miniati, I.; Czirjak, L.; Clements, P.; Denton, C.; Farge, D.; Fligelstone, K.; Foldvari, I.; Furst, D. E.; Muller-Ladner, U.; Seibold, J.; Silver, R. M.; Takehara, K.; Garay Toth, B.; Tyndall, A.; Valentini, Gabriele.; Van Den Hoogen, F.; Wigley, F.; Zulian, F.; Matucci-Cerinic, M.; and EUSTAR, Coauthors; Cuomo, Giovanna; Et, Al
Early onset neutropenia after mycophenolate mofetil in systemic sclerosis 1-gen-2009 Cuomo, Giovanna; Abignano, G; Valentini, Gabriele
Hypocomplementemia in Systemic sclerosis - Author reply 1-gen-2009 Cuomo, Giovanna; Abignano, G; Ruocco, L; Vettori, Serena; Valentini, Gabriele
Mostrati risultati da 21 a 40 di 210
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile